Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

harmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function. The Company believes that these biochemical features, together with preclinical and preliminary clinical data in patients with heart failure, suggest that CD-NP may have a favorable safety and efficacy profile relative to current therapies for ADHF. In addition to an initial indication for ADHF, CD-NP has potential utility in other indications which include preservation of cardiac function subsequent to acute myocardial infarction (AMI), and prevention of renal damage subsequent to cardiac surgery. We expect to initiate a Phase 2b study in patients with heart failure in 2009 and a Phase 2 study in AMI patients.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... ... 2015 , ... METTLER TOLEDO's web-based EasyFinder™ tool ... to a manageable shortlist of bench and floor scales and terminals. Specifying a ... with the customer’s industry and application. , Side-by-side product comparisons and an ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... ... soil fertility and the critical agricultural issues that face Africa, has been developed and ... ... -- AfricaFertilizer.org , a global forum to disseminate and exchange information on fertilizers, ...
... ... , ... , , , ... ...
... ... ... ... ...
Cached Biology Technology:AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 2AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 3AfricaFertilizer.org to Increase Agricultural Productivity and Knowledge Across the African Continent 4Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 2Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 3Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 4Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health 5BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million 2BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million 3BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million 4
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... 2009 The Center for Stem Cell & Regenerative Medicine ... Clinic (CC), University Hospitals (UH), and Athersys, Inc. has ... the Research Commercialization Program. The funding will help support ... four emerging and three pilot projects. This funding will ...
... scientists from Europe and China have gathered in Barcelona this ... research projects using data from ESA and Chinese Earth observation ... and the Ministry of Science and Technology (MOST) of China ... monitor and understand environmental phenomena in China. ,The symposium, held ...
... Although every cell in the body carries the genes ... small proportion of stem cells mature into those important immune-system ... Health and his colleagues have identified two "molecular motors" that ... cells. They published their findings June 19 in the online ...
Cached Biology News:CWRU receives $5 million from Ohio Third Frontier Commission 2CWRU receives $5 million from Ohio Third Frontier Commission 3Europe and China watching Earth together 2Pushmi-pullyu of B-cell development discovered 2
TCP-1 alpha (H-110)...
Request Info...
... Stem Cell (hESC) Starter Kit brings together many ... culturing hESCs as soon as possible. This set ... training courses around the world, including those supported ... been extensively tested using GIBCO's quality process and ...
Recombinant Feline IFN-alpha...
Biology Products: